Abstract:Hematopoietic stem cells (HSCs) have emerged as one of the most therapeutically significant adult stem cells, paving way for a range of novel curative regimens over decades. HSCs are transplanted, either directly or post restorative genetic engineering in order to repopulate a healthy hematopoietic homeostasis in patients with disorders affecting the blood and immune cells. Despite being an extensively studied system, the maintenance and expansion of functional HSCs ex vivo remains a major bottleneck. The challenge primarily stems from difficulties in reproducing HSC self-renewal divisions and gradual depletion of stemness characters, in vitro. Refining the in vitro culture can be particularly beneficial in the case of cord blood HSCs (CB-HSCs), as inadequate numbers in a single umbilical cord limits its therapeutic potential. In recent years, molecular dissection of HSC stemness has significantly improved in vitro hematopoietic stem and progenitor cells (HSPCs) culture. Despite such significant progress, lacunae exist in fully understanding all the underlying mechanisms and their interplay active in bona fide HSCs, and how it transforms when cells proliferate in culture. A new groundbreaking study titled "MYCT1 controls environmental sensing in human haematopoietic stem cells", published in Nature in June 2024, sheds light on this complex field. Through a series of experiments, including knock-down, overexpression, single-cell RNA sequencing, and transplantation, the study identifies a previously unknown role of the MYC target 1 (MYCT1) protein in HSC maintenance. This protein acts as a crucial regulator of human HSCs, with high expression in primitive HSCs and subsequently downregulated during ex vivo culture. The study reveals that MYCT1 plays a vital role in moderating endocytosis and environmental sensing in HSCs, processes thereby essential for maintaining HSC stemness and function. This commentary will discuss the implications of the new findings for cord blood expansion in cell therapies and HSPC culture for gene therapy applications, providing valuable insights for the field of hematopoietic regenerative medicine.

E3 ubiquitin ligase on the biological properties of hematopoietic stem cell

E3 Ubiquitin Ligases in Cancer and Implications for Therapies

Regulation of Hematopoietic Stem Cells Differentiation, Self-Renewal, and Quiescence Through the Mtor Signaling Pathway

Regulatory Role of E3 Ubiquitin Ligases in Normal B Lymphopoiesis and B-cell Malignancies.

The roles of E3 ubiquitin ligases in cancer progression and targeted therapy

Key roles of ubiquitination in regulating critical regulators of cancer stem cell functionality

E3 ubiquitin ligases in cancer stem cells: key regulators of cancer hallmarks and novel therapeutic opportunities

The Role of Deubiquitinating Enzymes in Hematopoiesis and Hematological Malignancies

The role of E3 ubiquitin ligase HECTD3 in cancer and beyond

E3 Ubiquitin Ligase-Mediated Regulation of Osteoblast Differentiation and Bone Formation

Emerging Roles of Epigenetic Regulators in Maintaining Hematopoietic Stem Cell Homeostasis

Regulation of Hematopoietic Stem Cell Fate and Malignancy

Targeting CSC-related transcription factors by E3 ubiquitin ligases for cancer therapy

E3 Ubiquitin Ligases in Endothelial Dysfunction and Vascular Diseases: Roles and Potential Therapies

Endocytosis as a critical regulator of hematopoietic stem cell fate —implications for hematopoietic stem cell and gene therapy

E3 ubiquitin ligases as cancer targets and biomarkers.

Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy

Immune regulation by protein ubiquitination: roles of the E3 ligases VHL and Itch

E3 Ubiquitin Ligases: Key Regulators of TGF Signaling in Cancer Progression

Deubiquitinases in Hematological Malignancies

Epigenetic regulation of hematopoietic stem cell fate